The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry
- PMID: 21067946
- PMCID: PMC4662380
- DOI: 10.1016/j.bcmd.2010.10.006
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry
Abstract
Purpose: Investigate the incidence of Parkinsonism among patients with Gaucher disease type 1 (GD1) and describe demographics, genotypes, and Gaucher disease (GD)-related characteristics for affected and non-affected patients.
Study type: Cohort study with age- and gender-matched nested case-control analysis. Calculation of event incidence, standardized morbidity ratio, and event-free survival (Kaplan-Meier).
Data source: The International Collaborative Gaucher Group (ICGG) Gaucher Registry data as of June 2010. Study cohort: GD1 patients with any report of Parkinsonism. Pre-matching control group: All GD1 patients with no report of Parkinsonism.
Results: The matched study cohort comprised of 68 patients with reports of Parkinsonism and 649 patients without Parkinsonism. Demographic and clinical characteristics suggest a milder GD phenotype in patients with Parkinsonism compared to the control group. The most prevalent GD1 genotype was N370S/N370S (39% for controls; 46% for patients with Parkinsonism). Patients with Parkinsonism were diagnosed with GD1 at a mean age of 37 years compared to 31 years in control patients. The standardized morbidity ratio for the development of Parkinsonism among all GD1 patients indicated an approximately 6 to 17 fold increase over that of 2 reference populations. The mean age of reported Parkinsonism onset was 57 years compared to 60 years in the general population (Lees, Hardy, and Revesz, 2009 [1]). The probability that a patient with GD1 will develop Parkinsonism before age 70 years is 5 to 7% and 9 to 12% before age 80 years.
Conclusions: The incidence of Parkinsonism among GD1 patients is significantly increased compared to two reference populations. GD1 patients with Parkinsonism have a later median age at GD diagnosis, later age at the start of treatment, and later age at death than patients with GD1 alone. The Gaucher-related clinical profile of GD1 patients with Parkinsonism is similar to or milder than the GD1 alone group. Therefore, severity of the common GD1 clinical manifestations does not appear to be predictive for the onset of Parkinsonism.
Copyright © 2010 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.J Bone Miner Res. 2012 Aug;27(8):1839-48. doi: 10.1002/jbmr.1680. J Bone Miner Res. 2012. PMID: 22692814
-
Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.S Afr Med J. 2022 Feb 2;112(1):13518. S Afr Med J. 2022. PMID: 35140000
-
The risk of Parkinson's disease in type 1 Gaucher disease.J Inherit Metab Dis. 2010 Apr;33(2):167-73. doi: 10.1007/s10545-010-9055-0. Epub 2010 Feb 23. J Inherit Metab Dis. 2010. PMID: 20177787 Free PMC article.
-
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842. Int J Mol Sci. 2022. PMID: 35628652 Free PMC article. Review.
-
Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry.Am J Hematol. 2015 Jul;90 Suppl 1:S12-8. doi: 10.1002/ajh.24063. Am J Hematol. 2015. PMID: 26096741 Review.
Cited by
-
Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson's disease.Brain Res. 2022 Apr 1;1780:147798. doi: 10.1016/j.brainres.2022.147798. Epub 2022 Jan 19. Brain Res. 2022. PMID: 35063468 Free PMC article. Review.
-
Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings.J Genet Couns. 2017 Dec;26(6):1165-1172. doi: 10.1007/s10897-017-0123-6. Epub 2017 Jun 30. J Genet Couns. 2017. PMID: 28667566
-
100 years of Lewy pathology.Nat Rev Neurol. 2013 Jan;9(1):13-24. doi: 10.1038/nrneurol.2012.242. Epub 2012 Nov 27. Nat Rev Neurol. 2013. PMID: 23183883
-
Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.Front Neurol. 2021 Jun 24;12:694764. doi: 10.3389/fneur.2021.694764. eCollection 2021. Front Neurol. 2021. PMID: 34248830 Free PMC article. Review.
-
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.Neuron. 2020 Mar 4;105(5):822-836.e7. doi: 10.1016/j.neuron.2019.12.004. Epub 2019 Dec 30. Neuron. 2020. PMID: 31899072 Free PMC article.
References
-
- Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055–2066. - PubMed
-
- Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 2000;160:2835–2843. - PubMed
-
- Weinreb NJ. The bone in Gaucher disease. Touch Briefings: European Musculoskeletal Review 2007 Issue. 2007;2:3–6.
-
- Grabowski GA, Petsko G, Kolodny EH. Gaucher disease. In: Scriver C, Beaudet A, Valle D, Slye W, editors. The Online Metabolic and Molecular Basis of Inherited Metabolic Disease. McGraw-Hill Publishers; 2010.
-
- Zimran A, Elstein D. Lipid storage diseases. In: Lichtman M, Kipps T, Seligsohn U, Kaushansky K, Prchal J, editors. Williams Hematology. Eighth Ed. New York: McGraw-Hill Publishers; 2011. pp. 1065–1071.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical